Skip to main content
. 2020 Mar 20;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949

Fig. 2.

Fig. 2

Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine only, in COVID-19 patients treated with hydroxychloroquine and azithromycin combination, and in COVID-19 control patients.